(2328664), J. L., (3520346), K. S., (36889), W. H., (1611796), Q. S., (12001241), Y. Q., (2027), Z. Z., . . . (3833092), E. D. (2025). Table 5_The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer.xlsx.
Chicago Style (17th ed.) Citation(2328664), Jingxian Li, Kun Shan (3520346), Wei Huang (36889), Qiang Su (1611796), Yuanjiong Qi (12001241), Zhihong Zhang (2027), Jianqiang Zhu (1669477), and E. Du (3833092). Table 5_The Combination Treatment of RC48 and STAT3 Inhibitor Acts as a Promising Therapeutic Strategy for Basal Bladder Cancer.xlsx. 2025.
MLA (9th ed.) Citation(2328664), Jingxian Li, et al. Table 5_The Combination Treatment of RC48 and STAT3 Inhibitor Acts as a Promising Therapeutic Strategy for Basal Bladder Cancer.xlsx. 2025.